Kiniksa Pharmaceuticals International Plc [KNSA] stock is trading at $30.22, up 1.51%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KNSA shares have gain 4.64% over the last week, with a monthly amount glided 12.59%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $40. Previously, Jefferies started tracking the stock with Buy rating on September 13, 2024, and set its price target to $40. On May 03, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $34 on the stock. BofA Securities reiterated its Buy rating and increased its price target to $40 on June 29, 2020. BofA/Merrill initiated its recommendation with a Buy and recommended $25 as its price target on April 01, 2020. Barclays started tracking with a Overweight rating for this stock on March 11, 2019, and assigned it a price target of $26. In a note dated December 12, 2018, Wedbush reiterated an Outperform rating on this stock and boosted its target price from $31 to $33.
Kiniksa Pharmaceuticals International Plc [KNSA] stock has fluctuated between $17.38 and $30.68 over the past year. Currently, Wall Street analysts expect the stock to reach $36.33 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $30.22 at the most recent close of the market. An investor can expect a potential return of 20.22% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] reported sales of 481.17M for the trailing twelve months, which represents a growth of 72.54%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.03%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.04 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.72 points at the first support level, and at 29.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.71, and for the 2nd resistance point, it is at 31.19.
Ratios To Look Out For
For context, Kiniksa Pharmaceuticals International Plc’s Current Ratio is 3.66. Further, the Quick Ratio stands at 3.43, while the Cash Ratio is 1.62. Considering the valuation of this stock, the price to sales ratio is 4.58, the price to book ratio is 4.81.
Transactions by insiders
Recent insider trading involved Quart Barry D, Director, that happened on Jun 11 ’25 when 12336.0 shares were sold. Director, Quart Barry D completed a deal on Jun 10 ’25 to sell 8212.0 shares. Meanwhile, Director Quart Barry D sold 6900.0 shares on Jun 09 ’25.
